Biopharmaceutical Contract Manufacturing Market
授權報價
| Single User | $4,799 USD |
| Multi User | $7,999 USD |
| Enterprise / Global Site Licence | $17,999 USD |
完整報告名稱與涵蓋範圍
Biopharmaceutical Contract Manufacturing Market (7th Edition) by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, Therapeutic Area, and Geographical Regions – Trends and Forecast Till 2035
報告摘要
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: OVERVIEW
As per Roots Analysis, the global biopharmaceutical contract manufacturing market is estimated to grow from USD 31.0 billion in 2026 to USD 63.9 billion by 2035, registering a CAGR of 8.3% across the forecast period.
Biopharmaceutical Contract Manufacturing Market: Growth and Trends
The growing global burden of chronic and complex diseases, along with the increasing adoption of advanced therapies such as monoclonal antibodies, cell and gene therapies, and nucleic acid-based drugs, continues to drive demand for biologics. As drug development pipelines expand across oncology, autoimmune, infectious, and rare-disease indications, pharmaceutical companies are increasingly outsourcing manufacturing operations to third-party specialists to meet accelerating production needs.
Analytical testing, toxicity testing, and fill / finish operations remain among the most frequently outsourced services, while demand for downstream process development services is also rising steadily. To leverage the expanding opportunity, smaller and mid-sized service providers are broadening their capabilities and forming strategic partnerships with larger players, enabling them to offer more comprehensive, end-to-end solutions.
Several forces are actively reshaping the competitive landscape. Continuous and intensified bioprocessing is rapidly moving from an emerging concept to standard industry practice, as manufacturers seek to offset pricing pressure through higher productivity and lower per-unit production costs. In parallel, geopolitical and trade dynamics including tariff exposure on pharmaceutical imports are prompting several CDMOs to expand or establish manufacturing capacity directly within the United States, reducing dependence on cross-border supply chains.
As outsourcing becomes an increasingly accepted and strategically favored business model across the biopharmaceutical industry, the contract manufacturing market is positioned for sustained, long-term growth.
Growth Drivers: Factors Fueling Market Expansion
The biopharmaceutical contract manufacturing market is being propelled by the growing demand for complex biologics and personalized medicine, and the need for specialized technical expertise that is often unavailable in-house. Contract manufacturers provide biotech and pharma companies with direct access to advanced bioprocessing technologies, including single-use bioreactors, continuous perfusion systems, and AI-enabled process automation, without requiring substantial upfront capital investments.
Additionally, the operational flexibility offered by CDMOs allows biopharmaceutical companies to scale production up or down in response to shifting demand, while reducing the overall cost burden associated with in-house manufacturing. This cost efficiency frees up capital that sponsors can redirect toward research and development, reinforcing the long-term strategic value of the outsourcing model and strengthening the growth trajectory of the broader market during the forecast period.
Market Challenges: Critical Barriers Hindering Progress
Despite favourable growth prospects, the market faces several challenges that could impede market growth. Some of the challenges include high capital requirements for specialized bioprocessing infrastructure, stringent and evolving regulatory expectations across geographies. Further, the technical complexity of scaling up novel modalities such as cell and gene therapies all add cost and time to manufacturing programs. Furthermore, escalating trade tensions and tariff exposure on pharmaceutical imports are compelling several manufacturers to re-evaluate their geographic footprint, creating near-term uncertainty around capacity planning and cost structures. Addressing these regulatory, technical, and geopolitical challenges will be critical for stakeholders seeking to capture the full commercial opportunity within this space.
Biopharmaceutical Contract Manufacturing Market: Key Insights
The report delves into the current state of the biopharmaceutical contract manufacturing market and identifies potential growth opportunities for distribution partners, channel intermediaries, and service integrators. Some key findings include:
• Biopharmaceutical CDMOs predominantly engage with pharmaceutical companies through direct commercial relationships and long-term supply agreements. This agreement limits the visibility that traditional distributors have into this segment, despite distributors' established reach into cold-chain logistics and specialty biologics handling.
• Specialty logistics and cold-chain service providers are emerging as critical enablers of biologic supply chains, given the temperature-sensitive nature of antibodies, cell therapies, and gene therapies that dominate CDMO output.
• Distributors and logistics partners seeking entry into this space must demonstrate validated cold-chain infrastructure and GMP-aligned handling protocols, reflecting the stringent quality requirements attached to biologic drug substances and drug products.
• The rapid expansion of commercial-scale manufacturing facilities across China and South Korea is increasing demand for regional distribution and supply chain partners capable of navigating local regulatory requirements and ensuring efficient logistics.
• Rising onshoring activity in the US, driven in part by tariff exposure on imported pharmaceutical products, is prompting CDMOs to reassess supplier and distribution networks closer to end markets, favouring partners with domestic infrastructure.
• Consolidation among large CDMOs through mergers and acquisitions is raising barriers to entry for smaller regional players, while creating openings for niche distributors and logistics providers with modality-specific or geography-specific expertise.
• Distributors and channel partners increasingly compete on value-added services including regulatory documentation support, temperature-controlled transport, and inventory management for high-value biologics rather than on logistics cost alone.
• The growing pipeline of ADCs, cell and gene therapies, and GLP-1-class biologics is expected to sustain elevated demand for specialized outsourcing and distribution infrastructure.
Recent Deal Activity Signalling Investor Momentum
• May 2026: Bristol Myers Squibb entered a licensing agreement with Jiangsu Hengrui Pharmaceuticals, gaining global rights to several early-stage oncology, hematology, and immunology programs outside Greater China, while Hengrui secured reciprocal rights to select BMS programs within the region.
• March 2026: Servier announced plans to acquire Day One Biopharmaceuticals, strengthening its rare oncology portfolio.
• January 2026: Mendra raised USD 82 million in Series A funding to build a portfolio of rare-disease assets.
• January 2026: Samsung Biologics agreed to acquire GSK's Human Genome Sciences facility in Rockville, Maryland, establishing a direct US manufacturing footprint.
• October 2025: Novartis (Switzerland) completed the acquisition of Tourmaline Bio (US), reflecting continued cross-border consolidation in the biologics space.
Collectively, these transactions underscore sustained investor and strategic-acquirer confidence in biologics manufacturing capacity, specifically onshoring and rare-disease / oncology pipelines themes directly relevant to distributors and investors evaluating exposure to this market.
Biopharmaceutical Contract Manufacturing Market Segments
The market sizing and opportunity analysis has been segmented across the following parameters:
By Type of Service Offered
• Drug Substance (API) Manufacturing
• Drug Product (FDF) Manufacturing
By Type of Biologic Manufactured
• Antibodies
• Proteins / Peptides
• Vaccines
• Cell Therapies
• Gene Therapies
• Other Biologics
By Type of Expression System Used
• Mammalian Expression Systems
• Microbial Expression Systems
• Other Expression Systems
By Scale of Operation
• Preclinical / Clinical Scale
• Commercial Scale
By Company Size
• Small Companies
• Mid-Sized Companies
• Large and Very Large Companies
By Therapeutic Area
• Oncological Disorders
• Cardiovascular Disorders
• Metabolic Disorders
• Infectious Diseases
• Autoimmune Disorders
• Neurological Disorders
• Genetic Disorders
• Other Disorders
By Geographical Regions
• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Australia
Biopharmaceutical Contract Manufacturing Market: Key Segments
Drug Substance (API) Leads the Market
Based on Roots Analysis market assessment and detailed clinical pipeline analysis, The drug substance (API) manufacturing segment currently secures approximately 60% of overall market revenue. This highest share reflects the growing preference among biologic developers to outsource upstream production. Lower capital investment requirements, faster access to cutting-edge bioprocessing technology, and more efficient utilization of specialized resources continue to reinforce this segment's leading position through the forecast period.
Antibodies Continue to Dominate the Types of Biologics Manufactured
According to our market analysis and detailed clinical pipeline analysis, antibodies account for around 60% of overall market revenue. This growth is underpinned by their central role in treating cancer, autoimmune disorders, infectious diseases, and a growing range of rare diseases. Looking ahead, cell therapies segment is likely to register a comparatively higher CAGR, as allogeneic approaches and increased automation help address current scalability constraints.
Mammalian Expression Systems Dominate the Market
Based on the Roots Analysis market report, mammalian expression systems hold over 80% of the overall market share, owing to their ability to closely replicate human protein-folding and post-translational modification processes, resulting in higher product quality, yield, and scalability for complex biologics. This segment is projected to grow at a CAGR of approximately 8.6% over the forecast period, outpacing several other platform types.
Commercial Scale Operations Lead the Market
Based on the Roots Analysis market report, commercial-scale manufacturing holds close to 90% of the overall market, reflecting the large volume of approved biologics currently in production. Preclinical and clinical-scale outsourcing, while smaller in current share, is expected to expand at a comparatively faster pace as a growing wave of biopharmaceuticals advances through the development pipeline toward eventual market approval.
Asia-Pacific Dominates the Market and Registers Higher CAGR
Asia-Pacific currently holds close to 40% of global market revenue share. This highest share is supported by considerably lower labor and raw material costs and comparatively lower facility construction costs relative to Western markets. China leads the region driven by the consistent support of substantial government investment through initiatives such as Healthy China 2030, alongside deep expertise in monoclonal antibody and biosimilar production.
Large and Very Large Companies Hold the Highest Market Share
Companies with large and very large operational scale currently account for nearly 60% of overall market revenue. This highest share reflects their established infrastructure, deep regulatory expertise, and long-standing sponsor relationships. Smaller and mid-sized players continue to expand their footprint through partnerships and targeted capability investments in order to compete for a growing share of outsourced work.
Example Players in Biopharmaceutical Contract Manufacturing Market
• AbbVie
• Agilent Technologies
• Boehringer Ingelheim
• Catalent
• Cipla
• Eurofins
• Fresenius Kabi
• Lonza
• Novartis
• Sandoz
• WACKER
• WuXi Biologics
A complete list of companies captured is available in the full report.
Expert Interview and Industry Insights
The opinions and insights presented in this study were shaped by discussions with multiple stakeholders across the value chain. The research report features detailed transcripts of interviews held with the following industry participants:
• Chief Executive Officer, Mid-Sized Company, Scotland
• Chief Executive Officer and Co-Founder, Small Company, Slovenia
• Former Chief Technical Officer, Large Company, US
• President, Mid-Sized Company, China
• Former Senior Director of Global Strategic Marketing, Large Company, US
• Former Senior Director of Commercial Strategy and Market Insights, Large Company, US
• Former Global Head of Sales and Marketing and Head of Business Development, Large Company, US
• Business Development Manager, Small Company, Spain
• Manager, Marketing and Sales, Mid-Sized Company, Germany
BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE
• Market Sizing and Opportunity Analysis: An in-depth analysis of the market focusing on key segments, including type of service offered, type of biologic manufactured, type of expression system used, scale of operation, company size, therapeutic area, and geographical regions.
• CDMO Landscape: A detailed assessment of active contract manufacturers, featuring information on year of establishment, company size, location of headquarters, and range of services offered.
• Company Profiles: In-depth profiles of prominent players engaged in biopharmaceutical contract manufacturing, covering year of establishment, headquarters location, company size, service portfolio, and key recent initiatives.
• Case Study I (Outsourcing of Biosimilars): A focused assessment of the biosimilars manufacturing landscape, covering development stages, regulatory requirements, outsourcing drivers, market impact, contract manufacturing service providers, and the key challenges associated with outsourcing biosimilar production.
• Case Study II (Comparison of Small and Large Molecule Drugs / Therapies): A concise comparison of small and large molecule drugs, highlighting their key characteristics, manufacturing processes, specifications, and associated manufacturing challenges.
• Case Study III (In-House Manufacturing): A concise assessment of in-house manufacturing and outsourcing strategies for biologics, covering their key benefits, risks, outsourcing trends, and manufacturing approaches to support informed make-versus-buy decisions.
• Make versus Buy Decision-Making Framework: A concise framework that evaluates in-house manufacturing versus outsourcing for biopharmaceutical production, using predefined assumptions, key parameters, and scenario-based analyses to support strategic manufacturing decisions.
• Partnerships and Collaborations: An analysis of partnerships and collaborations that have been inked by biopharmaceutical excipient manufacturers, based on several relevant parameters, such as such as year of partnership, type of partnership, type of excipient, and most active players.
• Funding and Investments Analysis: A detailed analysis of the funding and investments made in this domain, based on several relevant parameters, such as year of funding, type of funding, amount invested, purpose of funding, geography, most active players and leading investors.
• Recent Expansions Analysis: A comprehensive assessment of recent expansion initiatives undertaken by biopharmaceutical contract manufacturers. The chapter analyzes expansion trends by type, quarter, investment, and facility location, while identifying the most active companies based on the number of expansions and capital invested, providing insights into evolving manufacturing capacity and strategic growth priorities.
• Big Pharma Initiatives: An analysis of initiatives undertaken by leading pharmaceutical companies in the biopharmaceutical contract manufacturing market, based on several relevant parameters, such as year of initiative, type of initiative, quarter, partnership type, acquisition type, mergers and acquisitions, expansions, and the most active big pharma players (based on the number of initiatives, partnerships, mergers and acquisitions, and expansions).
• Capacity Analysis: A comprehensive assessment of the global installed capacity for biopharmaceutical contract manufacturing across company sizes, expression systems, and major geographic regions, including North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into regional manufacturing capabilities and capacity distribution.
• Demand Analysis: A comprehensive evaluation of demand across different manufacturing scales and examines the increasing requirements for emerging biologics, including antibody-drug conjugates (ADCs) and cell therapies, to identify future outsourcing and manufacturing opportunities.
• Total Cost of Ownership Analysis: A comprehensive evaluation of the total cost of ownership (TCO) for biopharmaceutical contract manufacturing organizations over a 20-year period. Based on predefined assumptions, key parameters, and a sample dataset, the chapter analyzes capital expenditure (CAPEX) and operational expenditure (OPEX) for mid-sized and large/very large manufacturing facilities, providing stakeholders with insights into long-term investment requirements and cost optimization strategies.
• SWOT Analysis: A strategic assessment of the biopharmaceutical contract manufacturing market, evaluating its key strengths, weaknesses, opportunities, and threats. The chapter compares the relative impact of each SWOT factor and provides actionable insights into the market's competitive position, growth potential, and strategic challenges.
Key Questions Answered in this Report
• Which are the leading companies in the biopharmaceutical contract manufacturing market?
• Which region dominates the market, and which is growing the fastest?
• What are the key trends observed in this market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by biopharmaceutical CDMOs?
• What is the current and future market size?
• What is the CAGR of this market through 2035?
• How is current and future market opportunity distributed across key segments?
• What opportunities exist for distributors and logistics partners entering this space?
Reasons to Buy this Report
This report is designed to give distributors, channel partners, and investors a decisive analytical edge in a fast-consolidating market. Its core differentiators include:
• Top-Down and Bottom-Up Triangulated Forecasting: Market estimates are built using a hybrid methodology that cross-validates top-down macro assessments against bottom-up, company-level capacity and demand data, minimizing forecast bias.
• Distribution and Channel-Partner Lens: Unlike conventional CDMO capability reports, this study explicitly maps the cold-chain, logistics, and value-added service opportunities available to distribution partners entering the biologics supply chain.
• 500+ Pages Across 35 Chapters: Comprehensive coverage spanning market sizing, competitive benchmarking, patent landscape, clinical trial activity, funding and M&A analysis, and regulatory / reimbursement mapping across 25+ countries.
• Primary Research-Backed Insights: Findings are validated through direct interviews with CEOs, CTOs, and commercial leaders across small, mid-sized, and large CDMOs, ensuring insights reflect real operating conditions rather than desk research alone.
• Actionable Segmentation: Seven-parameter segmentation (service type, biologic type, expression system, scale, company size, therapeutic area, geography) enables precise opportunity sizing for any go-to-market or investment thesis.
Additional Benefits
• Complementary PPT Insights Pack
• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older
目錄 Table of Contents
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
3. MARKET DYNAMICS
4. MACRO-ECONOMIC INDICATORS
5. EXECUTIVE SUMMARY
5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis
6. INTRODUCTION
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Company Size and Location of Headquarters
7.3. Biopharmaceutical Contract Manufacturers: Analysis of Key Players
7.3.1. Analysis by Compliance
7.3.2. Analysis by Type of Service Offered
7.3.3. Analysis by Type of Biologic Manufactured
7.3.4. Analysis by Scale of Operation
7.3.5. Analysis by Type of Expression System Used
7.3.6. Analysis by Type of Primary Container Offered
8. REGIONAL CAPABILITY ANALYSIS
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Biopharmaceutical Contract Manufacturers headquartered in North America
9.2.1. AbbVie
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.2. Agilent Technologies
9.2.3. Catalent
9.3. Biopharmaceutical Contract Manufacturers headquartered in Europe
9.3.1. Boehringer Ingelheim
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.2. Eurofins
9.3.3. Fresenius Kabi
9.3.4. Lonza
9.3.5. Novartis
9.3.6. Sandoz
9.3.7. WACKER
9.4. Biopharmaceutical Contract Manufacturers headquartered in Asia-Pacific
9.4.1. Cipla
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio
9.4.2. Wuxi Biologics
10. PROMINENT BIOPHARMACEUTICAL SECTORS
10.1. Chapter Overview
10.2. Bispecific Antibodies
10.3. Antibody Drug Conjugates (ADCs)
10.4. Cell Therapies
10.5. Gene Therapies
10.6. Viral Vectors
10.7. Plasmid DNA
11. CASE STUDY: OUTSOURCING OF BIOSIMILARS
11.1. Chapter Overview
11.2. Overview of Biosimilars
11.3. Development Stages of Biosimilars
11.4. Regulatory Requirements for Licensing of Biosimilars
11.5. Need for Outsourcing Manufacturing Operations
11.6. Impact of Biosimilars on the Global Contract Manufacturing Market
11.6.1. Biosimilars: Historical Trend of FDA Approvals
11.7. Biosimilars Contract Manufacturing Service Providers
11.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations
12. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES
12.1. Chapter Overview
12.2. Small Molecule and Large Molecule Drugs / Therapies
12.2.1. Comparison of General Characteristics
12.2.2. Comparison of Key Specifications
12.2.3. Comparison of Manufacturing Process
12.2.4. Comparison of Key Manufacturing Challenges
13. CASE STUDY: IN-HOUSE MANUFACTURING
13.1. Chapter Overview
13.2. In-House Manufacturing
13.2.1. Benefits Associated with In-House Manufacturing
13.2.2. Risks Associated with In-House Manufacturing
13.3. Outsourcing Trends in the Biopharmaceutical Industry
13.3.1. Types of Outsourcing Partners
13.4. Manufacturing Approaches Used for Approved Biologics
13.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing
14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
14.1. Chapter Overview
14.2. Key Assumptions and Parameters
14.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
14.3.1. Scenario 1
14.3.2. Scenario 2
14.3.3. Scenario 3
14.3.4. Scenario 4
14.4. Conclusion
15. PARTNERSHIPS AND COLLABORATIONS
16. FUNDING AND INVESTMENTS ANALYSIS
17. MERGERS AND ACQUISITIONS
18. RECENT EXPANSIONS
18.1. Chapter Overview
18.2. Type of Expansions
18.3. Biopharmaceutical Contract Manufacturers: Recent Expansions
18.3.1. Cumulative Trend of Expansions
18.3.2. Analysis by Type of Expansion
18.3.3. Analysis by Quarter and Type of Expansion
18.3.4. Analysis by Location of Facility (Region)
18.3.5. Analysis by Location of Facility (Country)
18.3.6. Analysis by Type of Expansion and Location of Facility (Region)
18.3.7. Analysis of Amount Invested by Year of Expansion
18.3.8. Analysis of Amount Invested by Type of Expansion
18.3.9. Most Active Players: Analysis by Number of Expansions
18.3.10. Most Active Players: Analysis by Amount Invested
19. BIG PHARMA INITIATIVES
20. CAPACITY ANALYSIS
21. DEMAND ANALYSIS
22. TOTAL COST OF OWNERSHIP
23. SWOT ANALYSIS
23.1. Chapter Overview
23.2. Comparison of SWOT Factors
23.3. Conclusion
24. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
24.3.1. Roots Analysis Perspective on Market Growth
24.3.2. Scenario Analysis
24.3.2.1. Conservative Scenario
24.3.2.2. Optimistic Scenario
24.4. Key Market Segmentations
25. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered
25.3.1. Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
25.3.2. Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation
26. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
26.3.1. Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
26.3.2. Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
26.3.3. Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
26.3.4. Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
26.3.5. Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
26.3.6. Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation
27. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used
27.3.1. Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
27.3.2. Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
27.3.3. Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation
28. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
28.3.1. Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
28.3.2. Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation
29. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
29.3.1. Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
29.3.2. Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
29.3.3. Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation
30. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Therapeutic Area
30.3.1. Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.3.2. Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.3.3. Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.3.4. Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.3.5. Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.3.6. Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.3.7. Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.3.8. Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation
31. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions
31.3.1. North America: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.1.1. US: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.1.2. Canada: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.1.3. Puerto Rico: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.2. Europe: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.2.1. Germany: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.2.2. UK: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.2.3. France: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.2.4. Spain: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.2.5. Italy: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.2.6. Rest of Europe: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.3. Asia-Pacific: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.3.1. China: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.3.2. South Korea: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.3.3. Japan: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.3.4. Singapore: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.3.5. Rest of Asia-Pacific: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.4. Rest of the World: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.4.1. Israel: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.4.2. Argentina: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.3.4.3. Africa: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.4. Market Dynamics Assessment
31.4.1. Market Movement Analysis
31.4.2. Penetration Growth (P-G) Matrix
31.5. Data Triangulation and Validation
32. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: NORTH AMERICA
32.1. Biopharmaceutical Contract Manufacturing Market in North America: Distribution by Type of Service Offered
32.1.1. Biopharmaceutical Contract Manufacturing Market in North America for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.1.2. Biopharmaceutical Contract Manufacturing Market in North America for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2. Biopharmaceutical Contract Manufacturing Market in North America: Distribution by Type of Biologic Manufactured
32.2.1. Biopharmaceutical Contract Manufacturing Market in North America for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2.2. Biopharmaceutical Contract Manufacturing Market in North America for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2.3. Biopharmaceutical Contract Manufacturing Market in North America for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2.4. Biopharmaceutical Contract Manufacturing Market in North America for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2.5. Biopharmaceutical Contract Manufacturing Market in North America for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2.6. Biopharmaceutical Contract Manufacturing Market in North America for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.3. Biopharmaceutical Contract Manufacturing Market in North America: Distribution by Type of Expression System Used
32.3.1. Biopharmaceutical Contract Manufacturing Market in North America for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.3.2. Biopharmaceutical Contract Manufacturing Market in North America for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.3.3. Biopharmaceutical Contract Manufacturing Market in North America for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.4. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
32.4.1. Biopharmaceutical Contract Manufacturing Market in North America for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.4.2. Biopharmaceutical Contract Manufacturing Market in North America for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.5. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
32.5.1. Biopharmaceutical Contract Manufacturing Market in North America for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.5.2. Biopharmaceutical Contract Manufacturing Market in North America for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.5.3. Biopharmaceutical Contract Manufacturing Market in North America for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6. Biopharmaceutical Contract Manufacturing Market: Distribution by Therapeutic Area
32.6.1. Biopharmaceutical Contract Manufacturing Market in North America for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6.2. Biopharmaceutical Contract Manufacturing Market in North America for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6.3. Biopharmaceutical Contract Manufacturing Market in North America for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6.4. Biopharmaceutical Contract Manufacturing Market in North America for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6.5. Biopharmaceutical Contract Manufacturing Market in North America for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6.6. Biopharmaceutical Contract Manufacturing Market in North America for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6.7. Biopharmaceutical Contract Manufacturing Market in North America for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6.8. Biopharmaceutical Contract Manufacturing Market in North America for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EUROPE
33.1. Biopharmaceutical Contract Manufacturing Market in Europe: Distribution by Type of Service Offered
33.1.1. Biopharmaceutical Contract Manufacturing Market in Europe for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.1.2. Biopharmaceutical Contract Manufacturing Market in Europe for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2. Biopharmaceutical Contract Manufacturing Market in Europe: Distribution by Type of Biologic Manufactured
33.2.1. Biopharmaceutical Contract Manufacturing Market in Europe for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2.2. Biopharmaceutical Contract Manufacturing Market in Europe for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2.3. Biopharmaceutical Contract Manufacturing Market in Europe for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2.4. Biopharmaceutical Contract Manufacturing Market in Europe for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2.5. Biopharmaceutical Contract Manufacturing Market in Europe for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2.6. Biopharmaceutical Contract Manufacturing Market in Europe for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.3. Biopharmaceutical Contract Manufacturing Market in Europe: Distribution by Type of Expression System Used
33.3.1. Biopharmaceutical Contract Manufacturing Market in Europe for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.3.2. Biopharmaceutical Contract Manufacturing Market in Europe for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.3.3. Biopharmaceutical Contract Manufacturing Market in Europe for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.4. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
33.4.1. Biopharmaceutical Contract Manufacturing Market in Europe for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.4.2. Biopharmaceutical Contract Manufacturing Market in Europe for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.5. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
33.5.1. Biopharmaceutical Contract Manufacturing Market in Europe for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.5.2. Biopharmaceutical Contract Manufacturing Market in Europe for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.5.3. Biopharmaceutical Contract Manufacturing Market in Europe for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6. Biopharmaceutical Contract Manufacturing Market: Distribution by Therapeutic Area
33.6.1. Biopharmaceutical Contract Manufacturing Market in Europe for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6.2. Biopharmaceutical Contract Manufacturing Market in Europe for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6.3. Biopharmaceutical Contract Manufacturing Market in Europe for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6.4. Biopharmaceutical Contract Manufacturing Market in Europe for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6.5. Biopharmaceutical Contract Manufacturing Market in Europe for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6.6. Biopharmaceutical Contract Manufacturing Market in Europe for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6.7. Biopharmaceutical Contract Manufacturing Market in Europe for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6.8. Biopharmaceutical Contract Manufacturing Market in Europe for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: ASIA-PACIFIC
34.1. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Service Offered
34.1.1. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.1.2. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Biologic Manufactured
34.2.1. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2.2. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2.4. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2.5. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2.6. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Expression System Used
34.3.1. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.3.2. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.3.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.4. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
34.4.1. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.4.2. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.5. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
34.5.1. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.5.2. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.5.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6. Biopharmaceutical Contract Manufacturing Market: Distribution by Therapeutic Area
34.6.1. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6.2. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6.4. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6.5. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6.6. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6.7. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6.8. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET: REST OF THE WORLD
35.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world: Distribution by Type of Service Offered
35.1.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.1.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world: Distribution by Type of Biologic Manufactured
35.2.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.2.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.2.3. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.2.4. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.2.5. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.3. Biopharmaceutical Contract Manufacturing Market in Rest of the world: Distribution by Type of Expression System Used
35.3.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.3.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.3.3. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.4. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
35.4.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.4.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.5. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
35.5.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.5.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.5.3. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6. Biopharmaceutical Contract Manufacturing Market: Distribution by Therapeutic Area
35.6.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.3. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.4. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.5. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.6. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Neurological
35.6.1. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.2. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.3. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.4. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.5. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.6. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.7. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6.8. Biopharmaceutical Contract Manufacturing Market in Rest of the world for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
**Detailed information on Chapters 32-35 is available in the Excel Data Packs shared along with the report**
36. CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES
37. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
38. CONCLUSION
39. EXECUTIVE INSIGHTS
39.1. Chapter Overview
39.2. RoslinCT
39.2.1. Company Snapshot
39.2.2. Interview Transcript: Peter Coleman, Chief Executive Officer
39.3. JAFRAL Biosolutions
39.3.1. Company Snapshot
39.3.2. Interview Transcript: Frenk Smrekar, Chief Executive Officer and Co-Founder
39.4. Discovery Life Sciences
39.4.1. Company Snapshot
39.4.2. Interview Transcript: Dominic Clarke, Former Chief Technical Officer, Cell and Gene Therapy
39.5. Bioworkshops
39.5.1. Company Snapshot
39.5.2. Interview Transcript: Nick Kotlarski, President and Chief Operating Officer
39.6. Aldevron
39.6.1. Company Snapshot
39.6.2. Interview Transcript: Jeff Briganti, Former Senior Director of Global Strategic Marketing
39.7. Resilience
39.7.1. Company Snapshot
39.7.2. Interview Transcript: Tarek Abdel-Gawad, Former Senior Director of Commercial Strategy and Market Insights
39.8. Minaris Regenerative Medicine
39.8.1. Company Snapshot
39.8.2. Interview Transcript: Luc St-Onge, Former Global Head of Sales and Marketing and Head of Business Development (Germany)
39.9. 53Biologics
39.9.1. Company Snapshot
39.9.2. Interview Transcript: Francisco Manuel Reyes Sosa, Business Development Manager
39.10. Richter-Helm BioLogics
39.10.1. Company Snapshot
39.10.2. Interview Transcript Antje Weingarth, Manager Marketing and Sales
40. APPENDIX I: TABULATED DATA
41. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
圖表清單 List of Tables & Figures
Table 6.1 Mammalian versus Microbial Expression Systems
Table 7.1 List of Biopharmaceutical Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 7.2 Key Biopharmaceutical Contract Manufacturers: Information on Compliance and Type of Service Offered
Table 7.3 Key Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 7.4 Key Biopharmaceutical Contract Manufacturers: Information on Scale of Operation and Type of Expression System Used
Table 7.5 Key Biopharmaceutical Contract Manufacturers: Information on Type of Primary Container Offered
Table 8.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 8.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 8.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Table 8.4 List of Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Table 9.1 Biopharmaceutical Contract Manufacturers: List of Companies Profiled
Table 9.2 AbbVie: Company Overview
Table 9.3 AbbVie: Service Portfolio
Table 9.4 Agilent Technologies: Company Overview
Table 9.5 Agilent Technologies: Service Portfolio
Table 9.6 Catalent: Company Overview
Table 9.7 Catalent: Service Portfolio
Table 9.8 Boehringer Ingelheim: Company Overview
Table 9.9 Boehringer Ingelheim: Service Portfolio
Table 9.10 Eurofins: Company Overview
Table 9.11 Eurofins: Service Portfolio
Table 9.12 Fresenius Kabi: Company Overview
Table 9.13 Fresenius Kabi: Service Portfolio
Table 9.14 Lonza: Company Overview
Table 9.15 Lonza: Service Portfolio
Table 9.16 Novartis: Company Overview
Table 9.17 Novartis: Service Portfolio
Table 9.18 Sandoz: Company Overview
Table 9.19 Sandoz: Service Portfolio
Table 9.20 WACKER: Company Overview
Table 9.21 WACKER: Service Portfolio
Table 9.22 Cipla: Company Overview
Table 9.23 Cipla: Service Portfolio
Table 9.24 WuXi Biologics: Company Overview
Table 9.25 WuXi Biologics: Service Portfolio
Table 10.1 Bispecific Antibody Therapeutics: Information on Drug Candidate, Developer, Developer, Phase of Development and Target Antigen
Table 10.2 Bispecific Antibody Therapeutics: Information on Clinical Drug Candidates, Target Indications, Therapeutic Areas and Disease Segments
Table 10.3 Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidate, Developer, Stage of Development and Target Antigen
Table 10.4 Bispecific Antibody Contract Manufacturers: List of Companies
Table 10.5 Commonly Used Cytotoxins for ADC Therapeutics
Table 10.6 Occupational Exposure Limit Bands, Safebridge Consultants
Table 10.7 Antibody-Drug Conjugates: Information on Developer, Stage of Development, Target Indication and Therapeutic Area
Table 10.8 Antibody-Drug Conjugate Developers: Information on Year of Establishment, Location of Headquarters (Country / Region), and Company Size
Table 10.9 ADC Contract Manufacturers: List of Companies
Table 10.10 Cell-based Therapies: Applications
Table 10.11 Cell-based Therapies: Commercialized Products
Table 10.12 Assessments for Key Cell Therapy Manufacturing Steps
Table 10.13 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 10.14 Industry Players: Information on Type of Immune Cell Offered
Table 10.15 Cell / Gene Therapy Contract Manufacturers: List of Companies
Table 10.16 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector Manufactured
Table 10.17 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 10.18 Plasmid DNA Contract Manufacturers: List of Companies
Table 11.1 List of Biosimilars Contract Manufacturing Service Providers
Table 12.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 12.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 12.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 13.1 List of FDA Approved Biologics (2016-2024)
Table 15.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations
Table 15.2 Partnerships and Collaborations: Information on Scale of Operation and Therapeutic Area
Table 15.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 16.1 Biopharmaceutical Contract Manufacturing: List of Funding and Investments, Q1 2024 – Q4 2025
Table 17.1 Biopharmaceutical Contract Manufacturing Organizations: List of Mergers and Acquisitions, Q1 2024 – Q4 2025
Table 17.2 Mergers and Acquisitions: Information on Key Value Drivers
Table 18.1 Biopharmaceutical Contract Manufacturing: List of Expansions
Table 19.1 List of Top Seven Big Pharma Players
Table 19.2 Big Pharma Players: List of Biopharmaceutical Contract Manufacturing Focused Initiatives, Q1 2024 – Q4 2025
Table 20.1 Biopharmaceutical Contract Manufacturers: Information on Mammalian and Microbial Production Capacities (Sample Dataset)
Table 20.2 Biopharmaceutical Contract Manufacturing: Average Mammalian and Microbial Production Capacity Based on Company Size
Table 20.3 Biopharmaceutical Contract Manufacturers: Information on Production Capacity (Sample Dataset)
Table 20.4 Biopharmaceutical Contract Manufacturing: Average Production Capacity Based on Company Size (Sample Dataset)
Table 20.5 Global Biopharmaceutical Contract Manufacturing Capacity: Distribution by Company Size (in liters)
Table 22.1 Total Cost of Ownership: Sample Dataset for Mid-sized Companies
Table 22.2 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 32.1 List of Virtual Biopharmaceutical Companies
Table 35.1 RoslinCT: Key Highlights
Table 35.2 JAFRAL Biosolutions: Key Highlights
Table 35.3 Discovery Life Sciences: Key Highlights
Table 35.4 Bioworkshops: Key Highlights
Table 35.5 Aldevron: Key Highlights
Table 35.6 Resilience: Key Highlights
Table 35.7 Minaris Regenerative Medicine: Key Highlights
Table 35.8 53Biologics: Key Highlights
Table 35.9 Richter-Helm BioLogics: Key Highlights
Table 40.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 40.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 40.3 Biopharmaceutical CMOs: Distribution by Location of Headquarters (Region)
Table 40.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 40.5 Biopharmaceutical Contract Manufacturers: Distribution by Company Size and Location of Headquarters (Region)
Table 40.6 Biopharmaceutical Contract Manufacturers: Distribution by Compliance
Table 40.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Table 40.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 40.9 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 40.10 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 40.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 40.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Primary Container Offered
Table 40.13 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 40.14 Biopharmaceutical Contract Manufacturing Facilities: Distribution of Type of Service Offered
Table 40.15 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 40.16 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 40.17 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Table 40.18 Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Table 40.19 Antibody-Drug Conjugates: Distribution by Stage of Development
Table 40.20 Antibody-Drug Conjugates: Distribution by Target Indication
Table 40.21 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Table 40.22 Industry Players: Distribution by Type of Immune Cell Offered
Table 40.23 Marketed and Clinical Stage Gene Therapies: Distribution by Stage of Development
Table 40.24 Marketed and Clinical Stage Gene Therapies: Distribution by Type of Vector Used
Table 40.25 Preclinical and Discovery Stage Gene Therapies: Distribution by Therapeutic Area
Table 40.26 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 40.27 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Table 40.28 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 40.29 Biosimilars: Historical Trend of FDA Approvals, 2015-2025
Table 40.30 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Table 40.31 Partnerships and Collaborations: Cumulative Trend of Partnerships, Q1 2024 - Q4 2025
Table 40.32 Partnerships and Collaborations: Distribution by Type of Partnership
Table 40.33 Partnerships and Collaborations: Distribution of Quarter and Type of Partnership
Table 40.34 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 40.35 Partnerships and Collaborations: Distribution by Scale of Operation
Table 40.36 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 40.37 Most Active Players: Distribution by Number of Partnerships
Table 40.38 Partnerships and Collaborations: Local and International Agreements
Table 40.39 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 40.40 Funding and Investments: Cumulative Trend of Funding, Q1 2024 - Q4 2025
Table 40.41 Funding and Investments: Cumulative Trend of Amount Invested, Q1 2024 - Q4 2025 (USD Million)
Table 40.42 Funding and Investments: Distribution of Instances by Type of Funding
Table 40.43 Funding and Investments: Distribution by Quarter and Type of Funding, Q1 2024 - Q4 2025 (USD Million)
Table 40.44 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 40.45 Funding and Investments: Distribution by Geography (Region)
Table 40.46 Funding and Investments: Distribution by Geography (Country)
Table 40.47 Most Active Players: Distribution by Number of Funding Instances
Table 40.48 Most Active Players: Distribution by Amount Raised (USD Million)
Table 40.49 Mergers and Acquisitions: Cumulative Trend of Mergers and Acquisitions, Q1 2024 – Q4 2025
Table 40.50 Mergers and Acquisitions: Distribution by Type of Agreement
Table 40.51 Mergers and Acquisitions: Distribution by Local and International Agreements
Table 40.52 Mergers and Acquisitions: Distribution by Intracontinental and Intercontinental Agreements
Table 40.53 Most Active Players: Distribution by Number of Agreements
Table 40.54 Mergers and Acquisitions: Distribution by Ownership Change Matrix
Table 40.55 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 40.56 Recent Expansions: Distribution by Cumulative Trend of Expansions
Table 40.57 Recent Expansions: Distribution by Type of Expansion
Table 40.58 Recent Expansions: Distribution by Year and Type of Expansion
Table 40.59 Recent Expansions: Distribution by Location of Facility (Region)
Table 40.60 Recent Expansions: Distribution by Location of Facility (Country)
Table 40.61 Recent Expansions: Distribution by Distribution by Type of Expansion and Location of Facility (Region)
Table 40.62 Recent Expansions: Distribution of Amount Invested by Year of Expansion
Table 40.63 Recent Expansions: Distribution of Amount Invested by Type of Expansion
Table 40.64 Most Active Players: Distribution by Number of Expansions
Table 40.65 Most Active Players: Distribution by Amount Invested
Table 40.66 Big Pharma Initiatives: Cumulative Trend of Initiatives
Table 40.67 Big Pharma Initiatives: Distribution by Type of Initiative
Table 40.68 Big Pharma Initiatives: Distribution by Quarter and Type of Initiative
Table 40.69 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Table 40.70 Big Pharma Initiatives: Distribution by Type of Partnership
Table 40.71 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Table 40.72 Big Pharma Initiatives: Distribution by Type of Acquisition
Table 40.73 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Table 40.74 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Expansions
Table 40.75 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Company Size
Table 40.76 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Type of Expression System Used
Table 40.77 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Geography
Table 40.78 Biopharmaceutical Contract Manufacturing Capacity in North America
Table 40.79 Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 40.80 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 40.81 Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Table 40.82 Global Demand for Biopharmaceutical Contract Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Table 40.83 Global Demand for Biopharmaceuticals: Distribution by Scale of Operation, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Table 40.84 Global Demand for ADC Therapeutics, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in kilograms)
Table 40.85 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 40.86 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Cells)
Table 40.87 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 40.88 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution of CAPEX (USD Million)
Table 40.89 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 40.90 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 40.91 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution of CAPEX (USD Million)
Table 40.92 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 40.93 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.94 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Table 40.95 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered
Table 40.96 Biopharmaceutical Contract Manufacturing Market for Drug Substance (API) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.97 Biopharmaceutical Contract Manufacturing Market for Drug Product (FDF) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.98 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Table 40.99 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.100 Biopharmaceutical Contract Manufacturing Market for Proteins / Peptides, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.101 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.102 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.103 Biopharmaceutical Contract Manufacturing Market for Gene Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.104 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.105 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used
Table 40.106 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.107 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.108 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.109 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
Table 40.110 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.111 Biopharmaceutical Contract Manufacturing Market for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.112 Biopharmaceutical Contract Manufacturing Market: Distribution by Therapeutic Area
Table 40.113 Biopharmaceutical Contract Manufacturing Market for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.114 Biopharmaceutical Contract Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.115 Biopharmaceutical Contract Manufacturing Market for Metabolic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.116 Biopharmaceutical Contract Manufacturing Market for Infectious Diseases, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.117 Biopharmaceutical Contract Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.118 Biopharmaceutical Contract Manufacturing Market for Neurological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.119 Biopharmaceutical Contract Manufacturing Market for Genetic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.120 Biopharmaceutical Contract Manufacturing Market for Other Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.121 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
Table 40.122 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.123 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.124 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.125 Biopharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions
Table 40.126 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.127 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.128 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.129 Biopharmaceutical Contract Manufacturing Market in Puerto Rico, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.130 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.131 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.132 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.133 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.134 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.135 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.136 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.137 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.138 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.139 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.140 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.141 Biopharmaceutical Contract Manufacturing Market in Singapore, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.142 Biopharmaceutical Contract Manufacturing Market in Rest of the Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.143 Biopharmaceutical Contract Manufacturing Market in Rest of the World, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.144 Biopharmaceutical Contract Manufacturing Market in Israel, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.145 Biopharmaceutical Contract Manufacturing Market in Argentina, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.146 Biopharmaceutical Contract Manufacturing Market in Africa, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.147 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Table 40.148 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market in 2023 (USD Billion)
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Types of Biopharmaceuticals
Figure 6.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 6.3 Stages of the Biomanufacturing Process
Figure 6.4 Types of Third Party Service Providers
Figure 6.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 7.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 7.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 7.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Figure 7.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Figure 7.5 Biopharmaceutical Contract Manufacturers: Distribution by Company Size and Location of Headquarters (Region)
Figure 7.6 Key Biopharmaceutical Contract Manufacturers: Distribution by Compliance
Figure 7.7 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Figure 7.8 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Figure 7.9 Key Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 7.10 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Figure 7.11 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 7.12 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Primary Container Offered
Figure 8.1 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Figure 8.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Figure 8.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 8.4 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
Figure 8.5 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
Figure 8.6 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Figure 8.7 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Figure 10.1 Basic Structure of an Antibody
Figure 10.2 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 10.3 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target indication
Figure 10.4 Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Figure 10.5 Structure of an Antibody Drug Conjugate (ADC)
Figure 10.6 Antibody-Drug Conjugates: Distribution by Stage of Development
Figure 10.7 Antibody-Drug Conjugates: Distribution by Target Indication
Figure 10.8 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Figure 10.9 Decentralized Manufacturing: Process Model
Figure 10.10 Cell Therapy Manufacturing: Types of Manufacturers
Figure 10.11 Cell Therapies: Challenges and Drivers
Figure 10.12 Cell Therapies: Potency as Critical Quality Attribute
Figure 10.13 Industry Players: Distribution by Type of Immune Cell Offered
Figure 10.14 Marketed and Clinical Stage Gene Therapies: Distribution by Stage of Development
Figure 10.15 Marketed and Clinical Stage Gene Therapies: Distribution by Type of Vector Used
Figure 10.16 Marketed and Clinical Stage Gene Therapies: Distribution by Therapeutic Area
Figure 10.17 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Figure 10.18 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Figure 10.19 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 11.1 Manufacturing Stages of a Biosimilar Product
Figure 11.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 11.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 11.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 11.5 Biosimilars: Historical Trend of FDA Approvals, 2015-2025
Figure 11.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 12.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2024
Figure 12.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 13.1 Benefits Associated with In-House Manufacturing
Figure 13.2 Risks Associated with In-House Manufacturing
Figure 13.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 14.1 Make versus Buy Decision Making Framework
Figure 14.2 Make versus Buy Decision Making Framework: Possible Scenarios
Figure 15.1 Partnerships and Collaborations: Cumulative Trend of Partnerships, Q1 2024 - Q4 2025
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Quarter and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 15.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 15.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.7 Most Active Players: Distribution by Number of Partnerships
Figure 15.8 Partnerships and Collaborations: Local and International Agreements
Figure 15.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 16.1 Funding and Investments Analysis: Cumulative Trend of Funding, Q1 2024 – Q4 2025
Figure 16.2 Funding and Investments Analysis: Cumulative Trend of Amount Invested, Q1 2024 – Q4 2025 (USD Million)
Figure 16.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 16.4 Funding and Investment Analysis: Distribution by Quarter and Type of Funding, Q1 2024 – Q4 2025
Figure 16.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 16.6 Funding and Investment Analysis: Distribution of Amount Invested by Quarter and Type of Funding, Q1 2024 – Q4 2025
Figure 16.7 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 16.8 Funding and Investment Analysis: Distribution by Geography (Country)
Figure 16.9 Most Active Players: Distribution by Number of Funding Instances
Figure 16.10 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 17.1 Mergers and Acquisitions: Cumulative Trend of Mergers and Acquisitions, Q1 2024 – Q4 2025
Figure 17.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 17.3 Mergers and Acquisitions: Distribution by Local and International Agreements
Figure 17.4 Mergers and Acquisitions: Intracontinental and Intercontinental Agreements
Figure 17.5 Most Active Players: Analysis by Number of Agreements
Figure 17.6 Mergers and Acquisitions: Ownership Change Matrix
Figure 17.7 Mergers and Acquisitions: Key Value Drivers
Figure 18.1 Recent Expansions: Cumulative Trend of Expansions, Q1 2024 – Q4 2025
Figure 18.2 Recent Expansions: Distribution by Type of Expansion
Figure 18.3 Recent Expansions: Distribution by Quarter and Type of Expansion
Figure 18.4 Recent Expansions: Distribution by Location of Facility (Region)
Figure 18.5 Recent Expansions: Distribution by Location of Facility (Country)
Figure 18.6 Recent Expansions: Distribution by Type of Expansion and Location of Facility (Region)
Figure 18.7 Recent Expansions: Distribution of Amount Invested by Quarter of Expansion
Figure 18.8 Recent Expansions: Distribution of Amount Invested by Type of Expansion
Figure 18.9 Most Active Players: Distribution by Number of Expansions
Figure 18.10 Most Active Players: Distribution by Amount Invested
Figure 19.1 Big Pharma Initiatives: Cumulative Trend of Big Pharma Initiatives
Figure 19.2 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 19.3 Big Pharma Initiatives: Distribution by Quarter and Type of Initiative
Figure 19.4 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Figure 19.5 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 19.6 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Figure 19.7 Big Pharma Initiatives: Distribution by Type of Acquisition
Figure 19.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Figure 19.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Expansions
Figure 19.10 Big Pharma Initiatives Summary
Figure 20.1 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Company Size
Figure 20.2 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Type of Expression System Used
Figure 20.3 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Geography
Figure 20.4 Biopharmaceutical Contract Manufacturing Capacity in North America
Figure 20.5 Biopharmaceutical Contract Manufacturing Capacity in Europe
Figure 20.6 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Figure 20.7 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Figure 21.1 Global Demand for Biopharmaceutical Contract Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Figure 21.2 Global Demand for Biopharmaceutical Contract Manufacturing: Distribution by Scale of Operation, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Figure 21.3 Global Demand for ADC Therapeutics, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in kilograms)
Figure 21.4 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 21.5 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
Figure 22.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 22.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 22.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 22.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 22.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 22.6 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 22.7 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 22.8 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 23.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 23.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 24.1 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 24.2 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
Figure 24.3 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Figure 25.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered
Figure 25.2 Biopharmaceutical Contract Manufacturing Market for Drug Substance (API) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 25.3 Biopharmaceutical Contract Manufacturing Market for Drug Product (FDF) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Figure 26.2 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.3 Biopharmaceutical Contract Manufacturing Market for Proteins / Peptides, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.4 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.5 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.6 Biopharmaceutical Contract Manufacturing Market for Gene Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.7 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used
Figure 27.2 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.3 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.4 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation
Figure 28.2 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.3 Biopharmaceutical Contract Manufacturing Market for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Therapeutic Area
Figure 29.2 Biopharmaceutical Contract Manufacturing Market for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.3 Biopharmaceutical Contract Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.4 Biopharmaceutical Contract Manufacturing Market for Metabolic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.5 Biopharmaceutical Contract Manufacturing Market for Infectious Diseases, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.6 Biopharmaceutical Contract Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.7 Biopharmaceutical Contract Manufacturing Market for Neurological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.8 Biopharmaceutical Contract Manufacturing Market for Genetic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.9 Biopharmaceutical Contract Manufacturing Market for Other Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size
Figure 30.2 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.3 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.4 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions
Figure 31.2 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.3 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.4 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.5 Biopharmaceutical Contract Manufacturing Market in Puerto Rico, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.6 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.7 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.8 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.9 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.10 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.11 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.12 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.13 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.14 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.15 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.16 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.17 Biopharmaceutical Contract Manufacturing Market in Singapore, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.18 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.19 Biopharmaceutical Contract Manufacturing Market in Rest of the World, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.20 Biopharmaceutical Contract Manufacturing Market in Israel, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.21 Biopharmaceutical Contract Manufacturing Market in Argentina, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.22 Biopharmaceutical Contract Manufacturing Market in Africa, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.23 Market Movement Analysis: Key Geographical Regions
Figure 31.24 Penetration-Growth (P-G) Matrix: Key Geographical Regions
Figure 36.1 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Figure 36.2 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market, till 2035 (USD Billion)
Figure 38.1 Concluding Remarks: Overall Market Landscape
Figure 38.2 Concluding Remarks: Partnerships and Collaborations
Figure 38.3 Concluding Remarks: Funding and Investments
Figure 38.4 Concluding Remarks: Mergers and Acquisitions
Figure 38.5 Concluding Remarks: Recent Expansions
Figure 38.6 Concluding Remarks: Capacity Analysis
Figure 38.7 Concluding Remarks: Demand Analysis
Figure 38.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 38.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Roots Analysis 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們